Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 20 Issue 6, June 2021

Volume 20 Issue 6

Vaccine adjuvants, inspired by the Review on p454.

Cover design: S. Harris

Comment

  • Comment |

    ENABLE is an antibacterial drug discovery and development consortium formed as a public–private partnership in 2014 as part of the Innovative Medicines Initiative (IMI) New Drugs for Bad Bugs (ND4BB) programme. With the project soon ending, here we provide a brief overview and reflect on its achievements, strengths and weaknesses.

    • Marie Olliver
    • Laura Griestop
    • Anders Karlén

News & Analysis

Research Highlights

Reviews

  • Review Article |

    Antisense technology is now beginning to deliver on its promise to treat diseases by targeting RNA. Here, Crooke and colleagues describe the key technological advances that have enabled this progress and discuss recent clinical trials that illustrate the impact of these advances on the performance of antisense oligonucleotides in a wide range of therapeutic applications.

    • Stanley T. Crooke
    • Brenda F. Baker
    • Xue-hai Liang
  • Review Article |

    This Review discusses how recent advances in understanding the activation of the innate immune system are shedding light on the immunological mechanisms of action of adjuvants and highlights how systems-based approaches are beginning to revitalize adjuvant design and development.

    • Bali Pulendran
    • Prabhu S. Arunachalam
    • Derek T. O’Hagan

Perspectives

  • Perspective |

    Despite the rapid growth of the engineered cell therapy sector, there are challenges to the broader industrialization of cells as medicines, especially in the treatment of solid tumours. This Perspective provides an industry perspective on the progress achieved by engineered T cell therapies and discusses strategies to industrialize their potential.

    • Cedrik M. Britten
    • Aiman Shalabi
    • Axel Hoos

Search

Quick links